{
  "docId": "019de076-5923-773b-8485-b914b8e85d5b",
  "docSlug": "aa767e092bc23262b7b522a6b0c001e5",
  "documentTitle": "MindMed | Results Presentation Deck | 20 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 20,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "key_messages",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide highlights regulatory alignment and specific methodological choices (no psychotherapy, placebo-controlled, dose-ranging).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-5923-773b-8485-b914b8e85d5b/13",
  "deckHref": "/decks/019de076-5923-773b-8485-b914b8e85d5b",
  "deckJsonHref": "/decks/019de076-5923-773b-8485-b914b8e85d5b.json",
  "deckAnchorHref": "/decks/019de076-5923-773b-8485-b914b8e85d5b#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.08,
        "x": 0.23,
        "y": 0.62
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9aba12f1-217f-4fca-b9ee-0cd2096291b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.08,
        "x": 0.23,
        "y": 0.32
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab68a1bb-6eca-4783-815f-3d1905e65b0e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.6,
        "x": 0.33,
        "y": 0.28
      },
      "kind": "list",
      "text": "FDA issues first draft guidance on clinical trials with psychedelic drugs. Agency provides clarity on regulatory expectations and R&D considerations. Guidance will help researchers design studies that will yield interpretable results.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d9fb354-7ae2-4adb-9418-be28624c9d1e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.6,
        "x": 0.33,
        "y": 0.58
      },
      "kind": "list",
      "text": "Phase 2b design aligns well with FDA guidance. No concurrent psychotherapy. Placebo-controlled. Dose-ranging.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fdd10db9-6c84-4b22-9350-af13de894ebb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "FDA guidance and Phase 2b dose-finding study align with MindMed's framework for designing well-controlled, scientifically rigorous trials to assess safety and efficacy in the psychedelic drug class",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "24a5197c-340d-4060-ae4e-faa4134f9c44",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. FDA. \"Psychedelic Drugs: Considerations for Clinical Investigations\"",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0d55816-f691-44d1-9f5d-5f9ec46d9180",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "MM-120 | Trial Design Milestones for Psychedelic Drug Class",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ed51257-8c97-4066-bda0-7c4e37f38d0b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "diagnostic-test",
      "slug": null,
      "matchId": "3fa0df87-bdca-467a-8d04-f160a0adf751",
      "evidence": "Aligning clinical trial design with regulatory guidance",
      "confidence": 0.7
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 8,
      "beatId": "43b0daed-c25d-4529-ba07-29b26d748e8f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Slides 8-14 provide evidence and proof of concept for MindMed's product candidates.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}